These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 3506266)

  • 21. [Treatment of multiple myeloma in stages I and II. Comparative study of an M-2 protocol and melphalan-prednisone].
    Montalbán C; Zapatero A; Blanco L; Sevilla F; García Laraña J; Odriozola J
    Sangre (Barc); 1984; 29(6):993-9. PubMed ID: 6549486
    [No Abstract]   [Full Text] [Related]  

  • 22. Weekly cyclophosphamide and alternate-day prednisone: an effective secondary therapy in multiple myeloma.
    Wilson K; Shelley W; Belch A; Brandes L; Bergsagel D; Klimo P; White D; Willan A
    Cancer Treat Rep; 1987 Oct; 71(10):981-2. PubMed ID: 3652060
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Myeloma with extramedullary extension coinciding with the normalization of serum paraproteins after treatment].
    Bernat S; Gozalbo T; García-Boyero R; Guinot M
    Sangre (Barc); 1998 Feb; 43(1):96-7. PubMed ID: 9577192
    [No Abstract]   [Full Text] [Related]  

  • 24. Alternating intravenous courses of melphalan and peptichemio in high-risk multiple myeloma (preliminary results).
    Franchi F; Seminara P; Rossi Fanelli F
    Anticancer Res; 1986; 6(2):297-8. PubMed ID: 3707066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multiple myeloma index: verification of a new prognostic approach with evaluation of treatment response.
    Bettini R; Tonolini M; Bernasconi M
    Haematologica; 1998 Aug; 83(8):708-13. PubMed ID: 9793254
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous involvement in multiple myeloma and bortezomib.
    Siniscalchi A; Fratoni S; Santeusanio G; Del Poeta G; de Fabritiis P; Caravita T
    Ann Hematol; 2009 Nov; 88(11):1137-9. PubMed ID: 19259673
    [No Abstract]   [Full Text] [Related]  

  • 29. The therapeutic efficacy of VBCMP-M2 protocol in multiple myeloma.
    Colović MD; Janković GM; Nikolov VS; Suvajdzić ND; Miletić VD
    Haematologia (Budap); 1994; 26(2):91-6. PubMed ID: 7890267
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alpha-2-interferon/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel R
    Cancer Treat Rep; 1986 Apr; 70(4):473-6. PubMed ID: 3698041
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on recent developments for patients with newly diagnosed multiple myeloma.
    Palumbo A; Magarotto V; Gay F; Falco P; Bringhen S; Boccadoro M
    Ann N Y Acad Sci; 2008 Sep; 1138():19-21. PubMed ID: 18837878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bortezomib, melphalan, and prednisone in elderly relapsed/refractory multiple myeloma patients: update of multicenter, open-label Phase 1/2 study.
    Grammatico S; Bringhen S; Vozella F; Siniscalchi A; Boccadoro M; Petrucci MT
    Leuk Lymphoma; 2017 Nov; 58(11):2738-2740. PubMed ID: 28402163
    [No Abstract]   [Full Text] [Related]  

  • 33. Comparison of melphalan and prednisone with vincristine, carmustine, melphalan, cyclophosphamide, and prednisone in the treatment of multiple myeloma: results of Eastern Cooperative Oncology Group Study E2479.
    Oken MM; Harrington DP; Abramson N; Kyle RA; Knospe W; Glick JH
    Cancer; 1997 Apr; 79(8):1561-7. PubMed ID: 9118039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Combination chemotherapy for multiple myeloma with melphalan, prednisone, cyclophosphamide, vincristine, and carmustine (BCNU) (M-2 protocol).
    Tirelli U; Crivellari D; Carbone A; Veronesi A; Galligioni E; Trovò MG; Tumolo S; Grigoletto E
    Cancer Treat Rep; 1982 Nov; 66(11):1971-3. PubMed ID: 6897205
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is aggressive chemotherapy more effective in the treatment of plasma cell myeloma?
    Bergsagel DE
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):159-61. PubMed ID: 2649372
    [No Abstract]   [Full Text] [Related]  

  • 36. [Results of combined treatment of advanced forms of multiple myeloma with vincristine, melphalan, cyclophosphamide and prednisone (VMCP) and with vincristine, doxorubicin, cyclophosphamide and prednisone (VDCP)].
    Robak T; Krykowski E; Płuzańska A; Olszańska-Skorek T; Urbańska-Ryś H; Polkowska-Kulesza E; Błasińska-Morawiec M; Mazurowa A
    Pol Tyg Lek; 1983 Apr; 38(16):481-4. PubMed ID: 6579509
    [No Abstract]   [Full Text] [Related]  

  • 37. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
    Palumbo A; Falco P; Corradini P; Falcone A; Di Raimondo F; Giuliani N; Crippa C; Ciccone G; Omedè P; Ambrosini MT; Gay F; Bringhen S; Musto P; Foà R; Knight R; Zeldis JB; Boccadoro M; Petrucci MT;
    J Clin Oncol; 2007 Oct; 25(28):4459-65. PubMed ID: 17785703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MR imaging of multiple myeloma in tumour mass measurement at diagnosis and during treatment.
    Carlson K; Aström G; Nyman R; Ahlström H; Simonsson B
    Acta Radiol; 1995 Jan; 36(1):9-14. PubMed ID: 7833177
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Myeloma and related disorders.
    Kyle RA; Durie BG; Boccadoro M; Pavlovsky S
    Rev Invest Clin; 1994 Apr; Suppl():46-51. PubMed ID: 7886308
    [No Abstract]   [Full Text] [Related]  

  • 40. [Therapy of multiple myeloma].
    La Verde G; Pulsoni A; Petrucci MT; Mandelli F
    Recenti Prog Med; 1997 Apr; 88(4):186-93. PubMed ID: 9206817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.